Amgen Inc. $AMGN Stock Holdings Lowered by StoneX Group Inc.

StoneX Group Inc. lessened its stake in Amgen Inc. (NASDAQ:AMGN) by 74.0% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 3,224 shares of the medical research company’s stock after selling 9,192 shares during the quarter. StoneX Group Inc.’s holdings in Amgen were worth $1,360,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Kornitzer Capital Management Inc. KS grew its stake in Amgen by 1.4% in the third quarter. Kornitzer Capital Management Inc. KS now owns 20,672 shares of the medical research company’s stock worth $8,713,000 after purchasing an additional 276 shares in the last quarter. Verus Capital Partners LLC increased its holdings in Amgen by 31.7% during the 3rd quarter. Verus Capital Partners LLC now owns 1,663 shares of the medical research company’s stock worth $701,000 after purchasing an additional 400 shares during the period. AlphaCentric Advisors LLC raised its position in Amgen by 3.9% during the 3rd quarter. AlphaCentric Advisors LLC now owns 2,455 shares of the medical research company’s stock valued at $1,035,000 after purchasing an additional 93 shares in the last quarter. Parallel Advisors LLC raised its position in Amgen by 6.0% during the 3rd quarter. Parallel Advisors LLC now owns 11,805 shares of the medical research company’s stock valued at $4,976,000 after purchasing an additional 666 shares in the last quarter. Finally, Abacus Wealth Partners LLC raised its position in Amgen by 13.1% during the 3rd quarter. Abacus Wealth Partners LLC now owns 1,258 shares of the medical research company’s stock valued at $530,000 after purchasing an additional 146 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New AHA 2026 data reinforced Repatha’s potential: an analysis found it cost-effective for high-risk patients without a prior heart attack or stroke, while a separate long-term analysis associated treatment with a 29% lower risk of major cardiovascular events in patients with ASCVD. The findings could support wider use, though the reported analyses do not guarantee future sales growth. Article: New Repatha data at AHA 2026
• Positive Sentiment: Amgen is heading into ACR week with a dazodalibep update expected November 11, creating a near-term clinical catalyst for its pipeline. The article headline does not specify the results, so the update’s impact will depend on the data. Article: Amgen stock heads into ACR week with dazodalibep update
• Positive Sentiment: An article highlighted experimental obesity drug MariTide’s potential to reduce dosing from 52 injections a year to four. If borne out in clinical development, less frequent dosing could be a competitive advantage; the drug remains experimental. Article: Amgen’s new drug could mean fewer shots for obesity patients
• Neutral Sentiment: Amgen shares rose in Monday trading but underperformed the broader market, indicating the move was not as strong as the overall market’s. Article: Amgen stock rises Monday, still underperforms market
• Negative Sentiment: ETFs were net sellers of $68.5 million of AMGN on November 5, a potential near-term supply headwind, although 51 funds bought shares and 20 sold. Article: ETFs are net sellers of Amgen

Amgen Trading Up 1.0%

Shares of NASDAQ:AMGN opened at $465.23 on Tuesday. Amgen Inc. has a 12-month low of $312.39 and a 12-month high of $483.99. The business’s fifty day simple moving average is $423.08 and its 200-day simple moving average is $378.80. The company has a market capitalization of $251.52 billion, a PE ratio of 26.99, a P/E/G ratio of 3.47 and a beta of 0.43. The company has a current ratio of 1.48, a quick ratio of 1.13 and a debt-to-equity ratio of 3.60.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 EPS for the quarter, topping the consensus estimate of $5.79 by $0.66. The firm had revenue of $10.37 billion during the quarter, compared to analyst estimates of $10.07 billion. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period in the previous year, the company posted $5.64 EPS. As a group, equities research analysts predict that Amgen Inc. will post 23.33 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.2%. The ex-dividend date is Friday, November 20th. Amgen’s payout ratio is 58.47%.

Insider Buying and Selling

In other Amgen news, SVP Rachna Khosla sold 1,252 shares of the business’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the transaction, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,666,817.72. The trade was a 16.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.85% of the company’s stock.

Analyst Ratings Changes

AMGN has been the subject of several research reports. Weiss Ratings upgraded Amgen from a “buy (b)” rating to a “buy (b+)” rating in a report on Thursday, October 8th. Barclays lifted their price objective on Amgen from $380.00 to $400.00 and gave the company an “equal weight” rating in a report on Wednesday, October 21st. HSBC lowered shares of Amgen from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $445.00 to $425.00 in a research note on Thursday, September 10th. Wall Street Zen raised shares of Amgen from a “hold” rating to a “buy” rating in a research report on Sunday, October 18th. Finally, JPMorgan Chase & Co. raised their target price on shares of Amgen from $350.00 to $425.00 and gave the company a “neutral” rating in a research report on Wednesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $422.76.

Amgen Company Profile

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases.

The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally.

Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A.